The global Omalizumab Biosimilars market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
This report aims to provide a comprehensive presentation of the global market for Omalizumab Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Omalizumab Biosimilars. This report contains market size and forecasts of Omalizumab Biosimilars in global, including the following market information:
Global Omalizumab Biosimilars Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global Omalizumab Biosimilars Market Sales, 2018-2023, 2024-2032, (Units)
Global top five Omalizumab Biosimilars companies in 2022 (%)
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
150 mg/mL Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Omalizumab Biosimilars include Roche, Novartis, Glenmark Pharmaceuticals, Selexis, Generium, CuraTeQ, Celltrion Healthcare, Alvotech and BiosanaPharma, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Omalizumab Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Omalizumab Biosimilars Market, by Type, 2018-2023, 2024-2032 ($ Millions) & (Units)
Global Omalizumab Biosimilars Market Segment Percentages, by Type, 2022 (%)
Global Omalizumab Biosimilars Market, by Application, 2018-2023, 2024-2032 ($ Millions) & (Units)
Global Omalizumab Biosimilars Market Segment Percentages, by Application, 2022 (%)
- Persistent Asthma
- Nasal Polyps
- Chronic Idiopathic Urticaria
Global Omalizumab Biosimilars Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions) & (Units)
Global Omalizumab Biosimilars Market Segment Percentages, By Region and Country, 2022 (%)
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Omalizumab Biosimilars revenues in global market, 2018-2023 (Estimated), ($ millions)
- Key companies Omalizumab Biosimilars revenues share in global market, 2022 (%)
- Key companies Omalizumab Biosimilars sales in global market, 2018-2023 (Estimated), (Units)
- Key companies Omalizumab Biosimilars sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Roche
- Novartis
- Glenmark Pharmaceuticals
- Selexis
- Generium
- CuraTeQ
- Celltrion Healthcare
- Alvotech
- BiosanaPharma
- Mabpharm
- CSPC Pharmaceutical Group
- Biomabs
- HisunPharm
- Grand Pharm
Outline of Major Chapters:
Chapter 1: Introduces the definition of Omalizumab Biosimilars, market overview.
Chapter 2: Global Omalizumab Biosimilars market size in revenue and volume.
Chapter 3: Detailed analysis of Omalizumab Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Omalizumab Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Omalizumab Biosimilars capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
